Natera, Inc. (NASDAQ:NTRA) Receives $249.20 Average PT from Analysts

Natera, Inc. (NASDAQ:NTRA) has been given an average rating of “Moderate Buy” by the eighteen research firms that are covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell rating, three have issued a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating on the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $254.4667.

A number of equities research analysts recently weighed in on the company. Canaccord Genuity Group restated a “buy” rating on shares of Natera in a report on Monday, January 12th. BTIG Research boosted their target price on Natera from $230.00 to $260.00 and gave the stock a “buy” rating in a research report on Friday, December 5th. Robert W. Baird raised their price target on Natera from $239.00 to $257.00 and gave the company an “outperform” rating in a research report on Friday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Natera in a research note on Thursday, January 22nd. Finally, TD Cowen reissued a “buy” rating on shares of Natera in a research note on Wednesday, January 7th.

Natera Stock Down 3.7%

Shares of NASDAQ:NTRA opened at $208.04 on Friday. The company has a market cap of $28.78 billion, a price-to-earnings ratio of -135.97 and a beta of 1.65. The firm’s 50-day simple moving average is $226.52 and its 200-day simple moving average is $204.17. Natera has a fifty-two week low of $125.38 and a fifty-two week high of $256.36.

Natera (NASDAQ:NTRA) last announced its quarterly earnings data on Thursday, February 26th. The medical research company reported $0.35 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.46) by $0.81. Natera had a negative return on equity of 16.71% and a negative net margin of 9.03%.The firm had revenue of $665.50 million for the quarter, compared to analyst estimates of $600.68 million. During the same quarter in the prior year, the company posted ($0.41) earnings per share. On average, research analysts forecast that Natera will post -1.49 EPS for the current year.

Key Headlines Impacting Natera

Here are the key news stories impacting Natera this week:

• Positive Sentiment: Quarterly beat — Natera reported Q4 revenue of $665.5M and GAAP EPS of $0.35, well ahead of street estimates (revenue ~$600.7M, EPS loss consensus). The beat supports near-term growth expectations and underpins the stock’s recent strength. Natera Reports Fourth Quarter and Full Year 2025 Financial Results
• Positive Sentiment: Favorable clinical data — New Signatera MRD data presented at ASCO GU highlight potential utility across genitourinary cancers (including bladder preservation), which may expand clinical adoption and long-term revenue for Natera’s oncology franchise. Signatera MRD Data at ASCO GU
• Positive Sentiment: Trial results — Natera reported results from the SINERGY trial, another clinical datapoint that could support commercial adoption of its assays. Natera Announces Results From the SINERGY Trial
• Positive Sentiment: Analyst upgrades/targets — Robert W. Baird raised its price target to $257 (outperform) and Wells Fargo raised its target to $215 (equal weight), signaling some sell-side confidence in upside from current levels. Benzinga – Analyst Price Target Changes
• Neutral Sentiment: Full-year revenue guidance roughly in line with consensus — Management issued FY2026 revenue guidance (roughly $2.6B–$2.7B), which appears consistent with street expectations and reduces upside surprise potential from guidance alone. (See Q4 release for guidance details.) Natera Reports Fourth Quarter and Full Year 2025 Financial Results
• Neutral Sentiment: Analyst consensus — Aggregated analyst coverage remains constructive (average “Moderate Buy”), which supports medium-term expectations but doesn’t preclude short-term volatility. Analyst Average Rating
• Negative Sentiment: Valuation and fundamentals concerns — Despite the beat, Natera still shows negative net margin and negative return on equity on a GAAP basis; combined with a high market capitalization and a recent run-up toward 52-week highs, investors may be taking profits. MarketBeat Q4 Coverage
• Negative Sentiment: Heavy intraday volume and selling pressure — Trading volume was well above average, consistent with a distribution day where some holders trimmed positions after the company’s strong quarter; that drove the stock lower despite the positives. (See intraday volume and price action for context.)

Insider Buying and Selling at Natera

In related news, insider Solomon Moshkevich sold 1,639 shares of the company’s stock in a transaction that occurred on Tuesday, February 3rd. The stock was sold at an average price of $230.77, for a total value of $378,232.03. Following the sale, the insider owned 137,847 shares of the company’s stock, valued at approximately $31,810,952.19. This represents a 1.18% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider John Fesko sold 3,594 shares of the business’s stock in a transaction on Tuesday, February 3rd. The stock was sold at an average price of $231.02, for a total value of $830,285.88. Following the completion of the transaction, the insider directly owned 178,081 shares of the company’s stock, valued at approximately $41,140,272.62. This trade represents a 1.98% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 360,719 shares of company stock worth $84,194,824 over the last ninety days. 5.63% of the stock is currently owned by company insiders.

Institutional Trading of Natera

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Horizon Investments LLC grew its holdings in shares of Natera by 22.0% during the fourth quarter. Horizon Investments LLC now owns 244 shares of the medical research company’s stock worth $56,000 after buying an additional 44 shares in the last quarter. Sound Income Strategies LLC boosted its position in Natera by 20.0% during the fourth quarter. Sound Income Strategies LLC now owns 270 shares of the medical research company’s stock worth $62,000 after acquiring an additional 45 shares during the last quarter. Savvy Advisors Inc. grew its stake in Natera by 3.1% in the 4th quarter. Savvy Advisors Inc. now owns 1,541 shares of the medical research company’s stock worth $353,000 after acquiring an additional 46 shares during the period. Siemens Fonds Invest GmbH raised its holdings in Natera by 3.1% in the 3rd quarter. Siemens Fonds Invest GmbH now owns 1,804 shares of the medical research company’s stock valued at $290,000 after acquiring an additional 54 shares during the last quarter. Finally, Alamea Verwaltungs GmbH raised its holdings in Natera by 2.9% in the 4th quarter. Alamea Verwaltungs GmbH now owns 2,229 shares of the medical research company’s stock valued at $515,000 after acquiring an additional 62 shares during the last quarter. Hedge funds and other institutional investors own 99.90% of the company’s stock.

Natera Company Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.